PD-L1xVEGF Drug: 1st Global Data for SCLC from BioNTech
BioNTech and BMS reveal promising first global data for their new pd-l1xvegf drug, a novel bispecific antibody targeting Small Cell Lung Cancer (SCLC) patients.
bristol myers squibb
Read More
PD-L1xVEGF Bispecific: 1st Global Data from BioNTech/BMS
BioNTech and BMS reveal promising first-in-human global data for their novel PD-L1xVEGF bispecific antibody, showing potential in treating advanced solid tumors.